Ignite Creation Date:
2024-05-06 @ 8:00 PM
Last Modification Date:
2024-10-26 @ 3:18 PM
Study NCT ID:
NCT06217666
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-01-22
First Post:
2024-01-09
Brief Title:
Study Examining the Safety and Toxicity of Stereotactic Body Radiotherapy SBRT Followed by PCX12 Immunotherapy Delivered by Intratumoral Injection for the Treatment of Patients With Locally Advanced Pancreatic Adenocarcinoma LAPC
Sponsor:
Haoming Carl Qiu
Organization:
University of Rochester
Study Overview
Official Title:
A Phase 1 Prospective Standard Dose Escalation Study Examining the Safety and Toxicity of Stereotactic Body Radiotherapy SBRT Followed by PCX12 Immunotherapy Delivered by Intratumoral Injection for the Treatment of Patients With Locally Advanced Pancreatic Adenocarcinoma LAPC
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether a new treatment combining radiation therapy with PCX12 is safe and tolerable
Detailed Description:
Single center open label escalating dosage of PCX12 with standard of care practice for subjects who are diagnosed with adenocarcinoma of the head of the pancreas Subjects with undergo standard of care radiation therapy and then start on PCX12 therapy starting at 200 ngkg of PCX12 escalating to a potential maximum dosage of 800 ngkg of PCX12 with adjacent tolerability and safety guidelines
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None